Explains the most user-reported phenomenon of semaglutide/tirzepatide therapy: 'food noise' — the constant intrusive thinking about food — drops away within days to weeks of starting, separate from and earlier than the weight loss itself. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide act through GLP-1R, a Gs-coupled GPCR (Drucker 2018 review). The peripheral effects — delayed gastric emptying (a key driver of early satiety + the sulfur-burp side effect from delayed protein digestion) and pancreatic β-cell glucose-dependent insulin secretion — are real, but the appetite-and-reward effects are CNS-mediated. Farr 2016 confirmed GLP-1R expression in the human hypothalamus, parietal cortex, and medulla; van Bloemendaal 2014 showed that GLP-1 receptor activation reduces fMRI signal in appetite- and reward-related brain regions (ventral striatum, insula, OFC, amygdala) in response to food cues. The phenomenology — 'I just don't think about food anymore' — maps cleanly onto this reward-cue dampening. Clinical magnitude: semaglutide 2.4 mg weekly produced a 14.9% body-weight reduction in STEP 1 (Wilding 2021); tirzepatide 15 mg weekly produced 20.9% in SURMOUNT-1 (Jastreboff 2022). GI side effects (nausea, sulfur burps from prolonged gastric retention, constipation, reflux) cluster early and usually attenuate over 8-12 weeks. Mechanism overlap with central reward explains the off-label observations of reduced alcohol craving and possibly other reward-driven behaviors (compulsive shopping, nail-biting) — an active research area.
Organ Systems
endocrine
digestive
nervous
Pathway Steps
semaglutide → GLP-1R activation (central + peripheral) — via GLP-1R on hypothalamic POMC/AgRP, NTS, β cells, gastric smooth muscle; long t½ via albumin binding. Semaglutide is a long-acting GLP-1 receptor agonist that resists DPP-4 degradation, giving a weekly half-life. It activates GLP-1Rs both peripherally and in the brain — and the realization that the central receptors drive most of the weight effect reframed these drugs from glucose-lowering to anti-obesity agents.
GLP-1R activation (central + peripheral) → delayed gastric emptying + early satiety + insulin secretion — via peripheral Gs → ↑cAMP slows gastric emptying (→ early fullness + sulfur burps); β-cell glucose-dependent insulin. Peripherally, GLP-1R activation slows gastric emptying and stimulates glucose-dependent insulin secretion while suppressing glucagon. Delayed emptying and the resulting early satiety reduce intake (and cause the nausea that is the main side effect), complementing the central appetite effects.
GLP-1R activation (central + peripheral) → hypothalamic POMC drive + AgRP suppression — via central GLP-1R on arcuate POMC → α-MSH release → MC4R activation; concurrent AgRP suppression. Centrally, GLP-1R agonism acts on the hypothalamic arcuate nucleus to increase anorexigenic POMC/CART signaling and suppress orexigenic AgRP/NPY neurons. This directly shifts the energy-balance set point toward reduced food intake — the core of the drugs’ appetite suppression.
hypothalamic POMC drive + AgRP suppression → reduced fMRI signal in ventral striatum / insula / OFC to food cues — via reward-circuit dampening — fMRI shows NAc / VTA / OFC ↓ activation to palatable food cues (van Bloemendaal 2014). Beyond the hypothalamus, GLP-1R signaling dampens food-reward circuitry: functional imaging shows reduced responses in the ventral striatum, insula, and orbitofrontal cortex to food cues. This blunting of reward salience — not just hunger — is a distinctive feature of GLP-1-based weight loss.
reduced fMRI signal in ventral striatum / insula / OFC to food cues → "food noise" quieting + intake reduction + weight loss — via STEP 1: semaglutide 14.9% loss at 68 wk; SURMOUNT-1: tirzepatide 20.9% at 72 wk; food-noise precedes weight loss. Patients describe the result as quieting of “food noise” — the intrusive, constant thoughts about eating — alongside smaller portions and weight loss. This subjective reward/craving change helps explain why GLP-1 agonists reduce intake more durably than appetite-suppressants acting on hunger alone.
tirzepatide (activator) — GLP-1 receptor + GIP receptor (dual agonist). dual GIP/GLP-1 agonism; produces larger weight reduction than pure GLP-1 RA at maximal dose (SURMOUNT-1: 20.9% vs ~15% for semaglutide); food-noise quieting reported equivalently
liraglutide (activator) — GLP-1 receptor. shorter t½ (~13 h, daily injection); the first GLP-1 RA approved for chronic weight management (Saxenda); central + peripheral mechanism identical to semaglutide
dulaglutide (activator) — GLP-1 receptor. weekly GLP-1 RA (Trulicity); approved for T2D; similar central food-noise and appetite-suppression mechanism though typically lower max dose than semaglutide for weight outcomes